{"id":"nabilone-capsules","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Dizziness"},{"rate":"25-50","effect":"Drowsiness"},{"rate":"10-25","effect":"Euphoria"},{"rate":"10-25","effect":"Dry mouth"},{"rate":"5-15","effect":"Ataxia"},{"rate":"5-15","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2218896","moleculeType":"Small molecule","molecularWeight":"372.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nabilone acts as a partial agonist at CB1 and CB2 cannabinoid receptors, primarily in the chemoreceptor trigger zone and vomiting center of the brain. This mechanism suppresses the signals that trigger nausea and emesis, making it effective for chemotherapy-induced nausea and vomiting (CINV) and other conditions associated with severe nausea.","oneSentence":"Nabilone is a synthetic cannabinoid that mimics THC and activates cannabinoid receptors in the central nervous system to reduce nausea and vomiting.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:27.536Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Post-operative nausea and vomiting"}]},"trialDetails":[{"nctId":"NCT05885685","phase":"PHASE4","title":"Investigating the Effects of Nabilone on Endocannabinoid Metabolism","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-10-31","conditions":"Healthy","enrollment":10},{"nctId":"NCT04516057","phase":"PHASE3","title":"Nabilone for Agitation Blinded Intervention Trial","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-02-01","conditions":"Alzheimer Disease, Agitation","enrollment":112},{"nctId":"NCT05273320","phase":"PHASE1","title":"Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities","status":"COMPLETED","sponsor":"Hsiang-Yuan Lin","startDate":"2022-03-17","conditions":"Intellectual Disability, Developmental Disability, Aggression","enrollment":20},{"nctId":"NCT04057456","phase":"PHASE3","title":"Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury","status":"COMPLETED","sponsor":"Eldon Loh, MD","startDate":"2023-03-01","conditions":"Spinal Cord Injuries, Neuropathic Pain","enrollment":14},{"nctId":"NCT05742698","phase":"PHASE2","title":"Nabilone for Agitation in Frontotemporal Dementia","status":"RECRUITING","sponsor":"Simon Ducharme, MD","startDate":"2023-03-07","conditions":"Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant, Primary Progressive Aphasia","enrollment":45},{"nctId":"NCT04880278","phase":"PHASE1, PHASE2","title":"Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder","status":"WITHDRAWN","sponsor":"New York State Psychiatric Institute","startDate":"2022-03-01","conditions":"Obsessive-Compulsive Disorder","enrollment":""},{"nctId":"NCT04801641","phase":"PHASE2","title":"A Pilot Trial of Nabilone for the Treatment of Obesity","status":"TERMINATED","sponsor":"Centre for Addiction and Mental Health","startDate":"2021-09-17","conditions":"Obesity","enrollment":24},{"nctId":"NCT05180968","phase":"PHASE3","title":"DIalysis Symptom COntrol-Pruritus Outcome Trial","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2022-08-02","conditions":"End Stage Renal Disease, Pruritus","enrollment":14},{"nctId":"NCT03422861","phase":"NA","title":"Nabilone Use For Acute Pain in Inflammatory Bowel Disease Patients","status":"UNKNOWN","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","startDate":"2023-12","conditions":"Inflammatory Bowel Diseases","enrollment":80},{"nctId":"NCT03251326","phase":"PHASE1, PHASE2","title":"Nabilone in Cannabis Users With PTSD","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2015-10","conditions":"Cannabis, Post Traumatic Stress Disorder","enrollment":4},{"nctId":"NCT03769896","phase":"PHASE2","title":"Nabilone for Non-motor Symptoms in Parkinson's Disease","status":"COMPLETED","sponsor":"Medical University Innsbruck","startDate":"2017-10-03","conditions":"Parkinson Disease","enrollment":48},{"nctId":"NCT03773796","phase":"PHASE3","title":"Nabilone for Non-motor Symptoms in Parkinson's Disease","status":"COMPLETED","sponsor":"Medical University Innsbruck","startDate":"2018-08-06","conditions":"Parkinson Disease","enrollment":22},{"nctId":"NCT01347762","phase":"PHASE2, PHASE3","title":"Nabilone for Cannabis Dependence: A Pilot Study","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2010-06","conditions":"Cannabis Dependence, Marijuana Dependence","enrollment":84},{"nctId":"NCT02802540","phase":"PHASE2, PHASE3","title":"Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2014-12","conditions":"Non-Small Cell Lung Cancer, Anorexia, Cachexia","enrollment":78},{"nctId":"NCT02115529","phase":"PHASE2","title":"Study of Prevention of Postoperative Nausea and Vomiting Using Cesamet","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2014-04","conditions":"Postoperative Nausea and Vomiting","enrollment":331},{"nctId":"NCT00480181","phase":"PHASE4","title":"Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2007-06","conditions":"Neuropathic Pain, Multiple Sclerosis","enrollment":50},{"nctId":"NCT01025700","phase":"PHASE2, PHASE3","title":"Nabilone & Marijuana Addiction","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2009-06","conditions":"Marijuana Smoking","enrollment":35}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CELLULITIS"}],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Nabilone Capsules","genericName":"Nabilone Capsules","companyName":"Eldon Loh, MD","companyId":"eldon-loh-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nabilone is a synthetic cannabinoid that mimics THC and activates cannabinoid receptors in the central nervous system to reduce nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV), Post-operative nausea and vomiting.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}